US - Glossary of Terms Flashcards
30 Day Hold
Period between filing an IND and FDA approval to proceed
120 day Safety Report
Amendment to NDA containing a safety update due after NDA is filed
180-day Exclusivity
Protects ANDA applicant from competition
351(k) Application
An abbreviated BLA for biological product demonstrated to be biosimilar
505(b)(2) Application
An application using investigations which were not performed by/approved for use by the applicant
Traditional 510(k)
Premarket submission demonstrating device safety
Special 510(k)
For device modifications (not affecting intended use or technology)
Abbreviated 510(k)
Demonstrates conformance with guidance documents
513 (g) Request for Info
Request for device classification
515 Program Initiative
Facilitates device reclassification action
522 Postmarket Surveillance Studies Program
Design, tracking, oversight and review responsibilities for medical device studies
AABB
American Association of Blood Banks
ACBTSA
Advisory Committee on Blood and Tissue Safety and Availability
Accelerated Approval
Allows earlier approval of drugs to treat serious diseases and those with an unmet medical need
Accredited Persons Program
Accredits third parties to conduct the primary 510(k) review for devices
ACE
Adverse Clinical Event
ACRP
Associate for Clinical Research Professionals
ACT
Applicable Clinical Trial
Action Letter
Letter that informs NDA or BLA sponsor of an agency decision (approvable, not approvable and clinical hold)
ADE
Adverse Drug Event (or Experience)
ADME
Absorption, Distribution, Metabolism and Excretion
ADR
Adverse Drug Reaction
AdvaMed
Advanced Medical Technology Association
Advisory Committee
Commitee used by FDA to obtain independent expert advise
AFDO
Association of Food and Drug Officials
AHRQ
Agency for Healthcare Research and Quality
AIA
America Invents Act (2011)
AIDC
Automatic Identification and Data Capture
AIP
Application Integrity Policy (regarding data reliability)
AMS
Agricultural Marketing Service
Analyte
In a clinical trial, the part of the sample the test is designated to find or measure
ANDA
Abbreviated New Drug Application (for generics)
Annual Report
Report that includes safety, efficacy, and labeling info, investigation summaries, CMC updates, and unpublished clinical trials
ANPR
Advance Notice of Proposed Rulemaking
APhA
American Pharmacists Association
APHIS
Animal and Plant Health Inspection Service
APLB
Advertising and Promotional Labeling branch (CBER)
AQL
Acceptable Quality Level
ASTM
American Society of Testing and Materials
ASR
Analyte Specific Reagent
AUT
Actual Use Trials
BA/BE Studies
Bioavailability / Bioequivalence studies
Bad Ad Program
program to ensure avertisers are truthful and not misleading (CDER’s - OPDP)
BCES
Blood Establishment Computer Software
BIMO
Bioresearch Monitoring Program
BIO
Biotechnology Industry Organization
BLA
Biologics License Application
BPCA
Best Pharmaceuticals for Children Act (2002)
BPCI Act
Biologics Price Competition and Innovation Act (2009)
BPDR
Biological Product Deviation Report
BsUFA
Biosimilar User Fee Act
CAP
Color Additive Petition
CBE-30
Changes being effected in 30 days (has potential to affect identity, strength, quality, purity, and potency adversely)
CBER
Center for Biologics Evaluation and Research
CBP
US Customs and Border Protection
CDER
Center for Drug Evaluation and Research
CDRH
Center for Devices and Radiological Health
CDx
Companion Diagnostic
CF
Consent Form (ICF, ICD)- info on risks and benefits (per Declaration of Helsinki)
CFG
Certificate to Foreign Government - to prove an exporting product can be legally marketed in the US
CFSAN
Center for Food Safety and Applied Nutrition
CH
Clinical Hold
CHIP
Children’s Healthcare Insurance Program
CHPA
Consumer Healthcare Products Association
CIOMS
Council for International Organizations of Medical Sciences
CIP
Clinical Investigation Plan
Class I Device
Low risk device class - requires controls to ensure safety and effectiveness
Class II Device
Medium risk device class - requires guidance docs, performance standards, postmarket surveillance
Class III Device
High risk device class- requires PMA. Life supporting, pose rise. Requires clinical trials
Clearance
Devices that receive marketing permission through the 510(k) process
CLIA
Clinical Laboratory Improvement Amendments (1988)
Clinical Hold
FDA order to delay proposed clinical investigation or suspend
Clinical Investigator
A medical researcher in charge of carrying out of a clinical trial protocol
CLSI
Clinical and Laboratory Standards Institute
CME
Continuing Medical Education
CMS
Centers for Medicare & Medicaid Services
COA
Clinical Outcomes Assessment- measures how patients feel or function
COE
Certificate of Exportability - issued by FDA to exporter
Common Rule
Requires IRB to ensure protocol is sufficient to protect a subject during the study
Consent Decree
Action carried out by DOJ. Correct cGMP violations by placing severe restrictions to ensure compliance
COOL
Country or Original Labeling
CPG
Compliance Policy Guide
CPGM
Compliance Program Guidance Manual
CPSC
Consumer Product Safety Commission
CRF
Case Report Form - data collected in a clinical trial
CR Letter
Complete Response letter - FDA dececision on NDA or ANDA
CSO
Consumer Safety Officer (Regulatory Project Manager)
CTD
Common Technical Document
CTP
Center for Tobacco Products
DARRTS
Document Archiving, Reporting and Regulatory Tracking System (CDER)
DBSQC
Division of Biological Standards and Quality Control (CBER)
DDT
Drug Development Tools
Declaration of Helsinki
Ethical principles for medical research on human subjects
Default Decree
A court order when a seized article is not claimed or defended
De Novo Process
Route to market for low-moderate risk devices in Class III
DESI
Drug Efficacy Study Implementation
DFUF
Device Facility User Fee
DHF
Design History File
DHR
Device History Record
DIA
Drug Information Association
DMC
Data Monitoring Committee
DMEPA
Division of Medication Error Prevention and Analysis (CDER)
DMPQ
Division of Manufacturing and Product Quality (CBER)
DMR
Device Master Record
DNCE
Division of Nonprescription Clinical Evaluation (CDER)
DNRD
Division of Nonprescription Regulation Development (CDER)
DRC
Direct Recall Classification Program (CBER)
DRISK
Division of Risk Management (CBER)
DRLS
Drug Registration and Listing System
Drug Competition Action Plan
Resolves regulatory obstacles during generic drug review
“Drug Facts” Label
Label for OTC drugs
DQSA
Drug Quality and Security Act (“Compounding Quality Act”)
DSHEA
Drug Supply Chain Security Act
DSNDCA
Dietary Supplement and Nonprescription Drug Consumer Protection Act
DTC
Direct to Consumer (advertising)
D-U-N-S
Data Universal Numbering System (9 digits by Dun & Bradstreet)
EA
Environmental Assessment
EAP
Expedited Access Pathway Program - voluntary for devices to address unmet medical needs
eBPDR
Electronic Biological Product Deviation Reports
EC
European Commission, European Community or Ethics Committee
ECO
Emergency Change Order
EFTA
European Free Trade Association
EIR
Establishment Inspection Report
ETASU
Elements to Ensure Safe Use
FAERS
FDA Adverse Event Reporting System
FALCPA
Food Allergen Labeling and Consumer Protection Act (2004)
FAP
Food Additive Petition
FAR
Field Alert Report
Fast Track
FDA program to facilitate development and NDA review process for treatment of life threatening conditions
FCA
False Claims Act
FCS
Food Contact Substance
FD&C Act
Federal Food, Drug and Cosmetic Act (1938)
FDAAA
Food and Drug Administration Amendments Act (1938)
FDA ESG
FDA Electronic Submissions Gateway
FDAMA
FDA Modernization Act (1997)
FDARA
FDA Reauthorization Act (2017)
FDSIA
FDA Safety and Innovation Act (2012)
FDLI
Food and Drug Law Institute
FIFRA
Federal Insecticide, Fungicide, and Rodenticide Act
FIH
First in Human study
FPI
Full Prescribing Information
FPLA
Fair Packaging and Labeling Act
FR
Federal Register
FSIS
Food Safety and Inspection Service
FSMA
Food Safety Modernization Act (2011)
FSMP
Food for Special Medical Purposes
FURLS
FDA Unified Registration and Listing System - medical device distributors
GAIN Act
Generating Antibiotic Incentives Now (2011)
GAO
Government Accountability Office
GARD
National Institute of Health Genetic and Rare Diseases
GE
Genetically Engineered
GO
Office of Global Regulatory Operations and Policy (CDER)
GPO
Government Printing Office and Group Purchasing Organization
GPR
General Purpose Reagents